Gritstone bio, Inc.

Welcome to Gridstone by your second quarter 2022 conference call. Please note this event is being recorded. It is now my pleasure to introduce Josh McDougall, Director of Investor Relations and Corporate Communications at Gridstone.

Please go ahead, sir.

Thank you, operator, and thank you, everyone, for joining us for Gritstone's conference call to discuss our financial results, clinical, and business updates for the second quarter of 2022. With me on the call today from Gritstone are Andrew Allen, co-founder, president, and CEO, Celia Economides, executive vice president and chief financial officer, and joining us for the Q&A portion will be Karen Youse, our head of R&D. Today, after the market closed, we issued a press release providing our second quarter 2022 financial results, clinical, and business updates. The press release is available on our website. I'd like to remind you that today's call is being webcast live via a link on Gritstone's investor relations website, where a replay will also be available after its completion. After our prepared remarks, we will open up the call for Q&A. During the course of this call, we will make forward-looking statements based on current expectations. These forward-looking statements are subject to a number of significant risks and uncertainties, and our actual results may differ materially from those described. We encourage you to review the risk factors in our most recent Forms 10Q filed with the U.S. Securities and Exchange Commission and available on our website. All statements on this call are made of as-today based on information currently available to us. Except as required by law, we disclaim any obligation to update such statements, even if our views change. With that, let me turn the call over to Andrew. Andrew?